UMB Announces Agreement to Acquire Heartland Financial
April 29, 2024 07:30 ET
|
Heartland Financial USA, Inc.
Largest acquisition in UMB history will increase total assets by more than 40% and significantly expand geographic footprint UMB investment community call today, Monday, April 29, at 7:30 a.m. (CT) /...
Heartland Financial USA, Inc. ("HTLF") Reports Quarterly Results as of March 31, 2024
April 29, 2024 07:30 ET
|
Heartland Financial USA, Inc.
First Quarter Highlights •Quarterly net income available to common stockholders of $49.7 million or $1.16 per common share•Adjusted earnings available to common stockholders of $52.4 million or $1.22...
Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia
April 29, 2024 07:25 ET
|
ALTERITY THERAPEUTICS LIMITED
– New Evidence Indicates ATH434 can Function as an Iron Chaperone to Redistribute Iron – MELBOURNE, Australia and SAN FRANCISCO, April 29, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX:...
EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases
April 29, 2024 07:00 ET
|
Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y., April 29, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the presentation of positive long-term results and subgroup analyses from the...
Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) Sublingual Film
April 29, 2024 07:00 ET
|
Aquestive Therapeutics, Inc.
Libervant is the first and only FDA approved orally administered rescue product for the treatment of seizure clusters in patients ages 2 to 5Announces immediate availability of Libervant 5mg, 7.5mg,...
Gritstone bio Announces Appointment of Stephen Webster to its Board of Directors
April 29, 2024 07:00 ET
|
Gritstone bio
EMERYVILLE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced...
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
April 29, 2024 07:00 ET
|
Cullinan Therapeutics, Inc.
CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced the...
Breckenridge Brewery Introduces New West Coast Style IPA ‘Ridge Runner’
April 29, 2024 07:00 ET
|
Tilray Brands, Inc.
Breckenridge Brewery Launches New Ridge Runner IPA inspired by the untamed beauty of Colorado’s trails and adventurous outdoor lifestyle behind the brand.
FibroGen to Report First Quarter 2024 Financial Results
April 29, 2024 07:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, April 29, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce first quarter 2024 financial results on Monday, May 6 after the market close. FibroGen will also conduct...
Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024
April 29, 2024 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, April 29, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral...